Science

Jun 27, 2025, 17:10

Myeloma Paper of the Day, June 27th, Suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of dual nanobody VHHs-based CAR T targeting BCMA shows ORR of 96.3% (26/27 (including many with high risk features)), median duration of remission of 11 months (2-36 months); 1-year OS rate of 61.1%, and PFS of 57.2%.”

Title: Efficacy and Safety of BCMA Nanobody CAR-T Cell Therapy in Relapsed or Refractory Plasma Cell Myeloma

Authors: Xian Zhang, Lin Wang, Junfang Yang, Xiaona Hu, Hui Wang, Lina Zhang, Xiaoge Zhou, Ying Liu, Qinglong Wang, Peihua Lu

You can read the Full Article in Blood Advances.

More posts featuring Robert Orlowski.

cancer CAR T-cell therapy Hui Wang Junfang Yang Lin Wang Lina Zhang Myeloma Myeloma Paper of the Day OncoDaily Oncology Peihua Lu Qinglong Wang Robert Orlowski Xian Zhang Xiaoge Zhou Xiaona Hu Ying Liu

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Yüksel Ürün: Science Is Better When It’s Shared

Oliver Bogler: Grant Tips